Abstract
Chronic microinflammation and its cellular hallmark, monocyte activation, contribute substantially to the tremendous burden of cardiovascular disease (CVD) in patients with chronic kidney diseases (CKD). Monocyte heterogeneity is widely acknowledged. Cell-surface expression of CD14 and CD16 defines three functionally and phenotypically distinct subsets of monocytes: classical (CD14++CD16−) monocytes, intermediate (CD14++CD16+) monocytes, and nonclassical (CD14+CD16++) monocytes. A growing body of circumstantial evidence suggests that intermediate monocytes, in particular, contribute to the development of atherosclerosis in the general population as well as in patients with CKD. Intermediate monocytes express a unique pattern of chemokine receptors that have been implicated in atherogenesis. Moreover, this subset of monocytes is predisposed to secrete proinflammatory cytokines. Findings from epidemiological studies indicate that numbers of intermediate monocytes increase with worsening renal function, and that high cell counts predict adverse outcomes in patients undergoing dialysis as well as in patients at early stages of CKD. Based on laboratory and clinical data, intermediate monocytes are a promising therapeutic target for CVD in patients with CKD.
Key Points
-
Monocytes and macrophages have a pivotal pathophysiological role in atherogenesis
-
Heterogeneity among monocytes exists—classical (CD14++CD16−) monocytes, intermediate (CD14++CD16+) monocytes and nonclassical (CD14+CD16++) monocytes can be differentiated by flow cytometry
-
Intermediate monocytes have proinflammatory features—laboratory data point to a subset-specific role of these cells in the development of atherosclerosis
-
A shift towards intermediate monocytes and nonclassical monocytes occurs in patients with chronic kidney disease (CKD); high intermediate monocyte counts predict adverse outcomes in these patients
-
Chronic microinflammation and its cellular hallmark, monocyte activation, are promising therapeutic targets for tackling cardiovascular disease in patients with CKD
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
de Jager, D. J. et al. Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA 302, 1782–1789 (2009).
Herzog, C. A. et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 80, 572–586 (2011).
Stenvinkel, P., Pecoits-Filho, R. & Lindholm, B. Coronary artery disease in end-stage renal disease: no longer a simple plumbing problem. J. Am. Soc. Nephrol. 14, 1927–1939 (2003).
Wanner, C. et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med. 353, 238–248 (2005).
Fellström, B. C. et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N. Engl. J. Med. 360, 1395–1407 (2009).
Zannad, F. et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int. 70, 1318–1324 (2006).
Baigent, C. et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377, 2181–2192 (2011).
Ronco, C., Haapio, M., House, A. A., Anavekar, N. & Bellomo, R. Cardiorenal syndrome. J. Am. Coll. Cardiol. 52, 1527–1539 (2008).
Libby, P., Ridker, P. M. & Hansson, G. K. Progress and challenges in translating the biology of atherosclerosis. Nature 473, 317–325 (2011).
Weber, C. & Noels, H. Atherosclerosis: current pathogenesis and therapeutic options. Nat. Med. 17, 1410–1422 (2011).
Woollard, K. J. & Geissmann, F. Monocytes in atherosclerosis: subsets and functions. Nat. Rev. Cardiol. 7, 77–86 (2010).
Hansson, G. K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352, 1685–1695 (2005).
Hansson, G. K. & Libby, P. The immune response in atherosclerosis: a double-edged sword. Nat. Rev. Immunol. 6, 508–519 (2006).
Combadière, C. et al. Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice. Circulation 117, 1649–1657 (2008).
Smith, J. D. et al. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc. Natl Acad. Sci. USA 92, 8264–8268 (1995).
Qiao, J. H. et al. Role of macrophage colony-stimulating factor in atherosclerosis: studies of osteopetrotic mice. Am. J. Pathol. 150, 1687–1699 (1997).
Wheeler, J. G., Mussolino, M. E., Gillum, R. F. & Danesh, J. Associations between differential leucocyte count and incident coronary heart disease: 1764 incident cases from seven prospective studies of 30,374 individuals. Eur. Heart J. 25, 1287–1292 (2004).
Passlick, B., Flieger, D. & Ziegler-Heitbrock, H. W. Identification and characterization of a novel monocyte subpopulation in human peripheral blood. Blood 74, 2527–2534 (1989).
Ziegler-Heitbrock, H. W. Definition of human blood monocytes. J. Leukoc. Biol. 67, 603–606 (2000).
Ancuta, P. et al. Fractalkine preferentially mediates arrest and migration of CD16+ monocytes. J. Exp. Med. 197, 1701–1707 (2003).
Geissmann, F., Jung, S. & Littman, D. R. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 19, 71–82 (2003).
Ziegler-Heitbrock, L. et al. Nomenclature of monocytes and dendritic cells in blood. Blood 116, e74–e80 (2010).
Zawada, A. M. et al. SuperSAGE evidence for CD14++CD16+ monocytes as a third monocyte subset. Blood 118, e50–e61 (2011).
Saarland University Medical Center and Saarland University Faculty of Medicine, Internal Medicine IV—nephrology and hypertention. CD16+ monocytes in atherogenesis and uremia. UKS [online].
Heimbeck, I. et al. Standardized single-platform assay for human monocyte subpopulations: lower CD14+CD16++ monocytes in females. Cytometry A 77, 823–830 (2010).
Human monocytes in health and disease. Human Monocytes In Health and Disease [online].
Wong, K. L. et al. Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets. Blood 118, e16–e31 (2011).
Fogg, D. K. et al. A clonogenic bone marrow progenitor specific for macrophages and dendritic cells. Science 311, 83–87 (2006).
Sunderkötter, C. et al. Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response. J. Immunol. 172, 4410–4417 (2004).
Swirski, F. M. et al. Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J. Clin. Invest. 117, 195–205 (2007).
Tacke, F. et al. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J. Clin. Invest. 117, 185–194 (2007).
Strauss-Ayali, D., Conrad, S. M. & Mosser, D. M. Monocyte subpopulations and their differentiation patterns during infection. J. Leukoc. Biol. 82, 244–252 (2007).
Afzal, A. R. et al. Common CCR5-del32 frameshift mutation associated with serum levels of inflammatory markers and cardiovascular disease risk in the Bruneck population. Stroke 39, 1972–1978 (2008).
González, P. et al. Genetic variation at the chemokine receptors CCR5/CCR2 in myocardial infarction. Genes Immun. 2, 191–195 (2001).
Pai, J. K. et al. Polymorphisms in the CC-chemokine receptor-2 (CCR2) and -5 (CCR5) genes and risk of coronary heart disease among US women. Atherosclerosis 186, 132–139 (2006).
Muntinghe, F. L. et al. CCR5 deletion protects against inflammation-associated mortality in dialysis patients. J. Am. Soc. Nephrol. 20, 1641–1649 (2009).
Cros, J. et al. Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity 33, 375–386 (2010).
Mosig, S. et al. Monocytes of patients with familial hypercholesterolemia show alterations in cholesterol metabolism. BMC Med. Genomics 1, 60 (2008).
Steppich, B. et al. Selective mobilization of CD14+CD16+ monocytes by exercise. Am. J. Physiol. Cell Physiol. 279, C578–C586 (2000).
Ancuta, P., Wang, J. & Gabuzda, D. CD16+ monocytes produce IL-6, CCL2, and matrix metalloproteinase-9 upon interaction with CX3CL1-expressing endothelial cells. J. Leukoc. Biol. 80, 1156–1164 (2006).
Settles, M. et al. Different capacity of monocyte subsets to phagocytose iron-oxide nonoparticles. PLoS ONE 6, e25197 (2011).
Schlitt, A. et al. CD14+CD16+ monocytes in coronary artery disease and their relationship to serum TNF-α levels. Thromb. Haemost. 92, 419–424 (2004).
Hristov, M. et al. Circulating monocyte subsets and cardiovascular risk factors in coronary artery disease. Thromb. Haemost. 104, 412–414 (2010).
Rogacev, K. S. et al. Monocyte heterogeneity in obesity and subclinical atherosclerosis. Eur. Heart J. 31, 369–376 (2010).
Poitou, C. et al. CD14dimCD16+ and CD14+CD16+ monocytes in obesity and during weight loss: relationships with fat mass and subclinical atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 31, 2322–2330 (2011).
Kashiwagi, M. et al. Association of monocyte subsets with vulnerability characteristics of coronary plaques as assessed by 64-slice multidetector computed tomography in patients with stable angina pectoris. Atherosclerosis 212, 171–176 (2010).
Imanishi, T. et al. Association of monocyte subset counts with coronary fibrous cap thickness in patients with unstable angina pectoris. Atherosclerosis 212, 628–635 (2010).
Tsujioka, H. et al. Impact of heterogeneity of human peripheral blood monocyte subsets on myocardial salvage in patients with primary acute myocardial infarction. J. Am. Coll. Cardiol. 54, 130–138 (2009).
Liu, Y. et al. Association between circulating monocyte subsets and in-stent restenosis after coronary stent implantation in patients with ST-elevation myocardial infarction. Circ. J. 74, 2585–2591 (2010).
Rogacev, K. S. & Heine, G. H. Human monocyte heterogeneity—a nephrological perspective. Nephrol. Ther. 6, 219–225 (2010).
Meuer, S. C., Hauer, M., Kurz, P., Meyer zum Büschenfelde, K. H. & Köhler, H. Selective blockade of the antigen-receptor-mediated pathway of T cell activation in patients with impaired primary immune responses. J. Clin. Invest. 80, 743–749 (1987).
Kato, S. et al. Aspects of immune dysfunction in end-stage renal disease. Clin. J. Am. Soc. Nephrol. 3, 1526–1533 (2008).
Girndt, M. et al. Production of interleukin-6, tumor necrosis factor α and interleukin-10 in vitro correlates with the clinical immune defect in chronic hemodialysis patients. Kidney Int. 47, 559–565 (1995).
Girndt, M., Sester, U., Kaul, H. & Köhler H. Production of proinflammatory and regulatory monokines in hemodialysis patients shown at a single-cell level. J. Am. Soc. Nephrol. 9, 1689–1696 (1998).
Stenvinkel, P. et al. Il-10, Il-6, and TNF-α: central factors in the altered cytokine network of uremia—the good, the bad, and the ugly. Kidney Int. 67, 1216–1233 (2005).
Kimmel, P. L. et al. Immunologic function and survival in hemodialysis patients. Kidney Int. 54, 236–244 (1998).
Zoccali, C., Tripepi, G. & Mallamaci, F. Dissecting inflammation in ESRD: do cytokines and C-reactive protein have a complementary prognostic value for mortality in dialysis patients? J. Am. Soc. Nephrol. 17 (Suppl. 3), S169–S173 (2006).
Girndt, M., Kohler, H., Schiedhelm-Weick, E., Meyer zum Büschenfelde, K. H. & Fleischer, B. T cell activation defect in hemodialysis patients: evidence for a role of the B7/CD28 pathway. Kidney Int. 44, 359–365 (1993).
Mozar, A. et al. High extracellular inorganic phosphate concentration inhibits RANK–RANKL signaling in osteoclast-like cells. J. Cell. Physiol. 215, 47–54 (2008).
Nockher, W. A. & Scherberich, J. E. Expanded CD14+ CD16+ monocyte subpopulation in patients with acute and chronic infections undergoing hemodialysis. Infect. Immun. 66, 2782–2790 (1998).
Sester, U. et al. Strong depletion of CD14+CD16+ monocytes during haemodialysis treatment. Nephrol. Dial. Transplant. 16, 1402–1408 (2001).
Ramírez, R. et al. Stress-induced premature senescence in mononuclear cells from patients on long-term hemodialysis. Am. J. Kidney Dis. 45, 353–359 (2005).
Carracedo, J. et al. On-line hemodiafiltration reduces the proinflammatory CD14+CD16+ monocyte-derived dendritic cells: a prospective, crossover study. J. Am. Soc. Nephrol. 17, 2315–2321 (2006).
Brauner, A., Lu, Y., Halldén, G., Hylander, B. & Lundahl, J. Difference in the blood monocyte phenotype between uremic patients and healthy controls: its relation to monocyte differentiation into macrophages in the peritoneal cavity. Inflammation 22, 55–66 (1998).
Kawanaka, N., Nagake, Y., Yamamura, M. & Makino, H. Expression of Fc gamma receptor III (CD16) on monocytes during hemodialysis in patients with chronic renal failure. Nephron 90, 64–71 (2002).
Heine, G. H. et al. CD14++CD16+ monocytes but not total monocyte numbers predict cardiovascular events in dialysis patients. Kidney Int. 73, 622–629 (2008).
Nockher, W. A., Wiemer, J. & Scherberich, J. E. Haemodialysis monocytopenia: differential sequestration kinetics of CD14+CD16+ and CD14++ blood monocyte subsets. Clin. Exp. Immunol. 123, 49–55 (2001).
Koc, M. et al. Toll-like receptor expression in monocytes in patients with chronic kidney disease and haemodialysis: relation with inflammation. Nephrol. Dial. Transplant. 26, 955–963 (2011).
Rogacev, K. S. et al. CD14++CD16+ monocytes and cardiovascular outcome in patients with chronic kidney disease. Eur. Heart J. 32, 84–92 (2011).
Ulrich, C., Heine, G. H., Seibert, E., Fliser, D. & Girndt, M. Circulating monocyte subpopulations with high expression of angiotensin-converting enzyme predict mortality in patients with end-stage renal disease. Nephrol. Dial. Transplant. 25, 2265–2272 (2010).
Rogacev, K. S. et al. Haemodialysis-induced transient CD16+ monocytopenia and cardiovascular outcome. Nephrol. Dial. Transplant. 24, 3480–3486 (2009).
Ulrich, C., Seibert, E., Heine, G. H., Fliser, D. & Girndt, M. Monocyte angiotensin converting enzyme expression may be associated with atherosclerosis rather than arteriosclerosis in hemodialysis patients. Clin. J. Am. Soc. Nephrol. 6, 505–511 (2011).
Ulrich, C. et al. Increased expression of monocytic angiotensin-converting enzyme in dialysis patients with cardiovascular disease. Nephrol. Dial. Transplant. 21, 1596–1602 (2006).
Mosig, S. et al. Different functions of monocyte subsets in familial hypercholesterolemia: potential function of CD14+ CD16+ monocytes in detoxification of oxidized LDL. FASEB J. 23, 866–874 (2009).
Author information
Authors and Affiliations
Consortia
Contributions
All authors contributed to the review and/or editing of the manuscript before submission. G. H. Heine researched data for the article, provided a substantial contribution to the discussions of content and wrote the article. D. Fliser also contributed to discussions of content and writing the article.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Heine, G., Ortiz, A., Massy, Z. et al. Monocyte subpopulations and cardiovascular risk in chronic kidney disease. Nat Rev Nephrol 8, 362–369 (2012). https://doi.org/10.1038/nrneph.2012.41
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2012.41
This article is cited by
-
Threshold-modifying effect of the systemic inflammatory response index on kidney function decline in hypertensive patients
European Journal of Medical Research (2024)
-
Exercise and chronic kidney disease: potential mechanisms underlying the physiological benefits
Nature Reviews Nephrology (2023)
-
Modulation of monocyte subtypes in diabetes after non-surgical periodontal treatment
Clinical Oral Investigations (2023)
-
Intradialytic cycling does not exacerbate microparticles or circulating markers of systemic inflammation in haemodialysis patients
European Journal of Applied Physiology (2022)
-
Inflammatory biomarkers in staging of chronic kidney disease: elevated TNFR2 levels accompanies renal function decline
Inflammation Research (2022)